Chromosomal instability determines taxane response

Charles Swanton(Cancer Research UK), Barbara Nicke(Cancer Research UK), Marion Schuett(Koblenz University of Applied Sciences), Aron C. Eklund(Technical University of Denmark), Charlotte K.Y. Ng(University of Cambridge), Qiyuan Li(Technical University of Denmark), Thomas J. Hardcastle(University of Cambridge), Alvin Lee(Cancer Research UK), Rajat Roy(Cancer Research UK), Philip East(Cancer Research UK), Maik Kschischo(Koblenz University of Applied Sciences), David Endesfelder(Koblenz University of Applied Sciences), Paul G. Wylie(University of Hertfordshire), Se Nyun Kim, Jie-Guang Chen(Wenzhou Medical University), Michael Howell(Cancer Research UK), Thomas Ried(National Institutes of Health), Jens K. Habermann(University Hospital Schleswig-Holstein), Gert Auer(Karolinska Institutet), James D. Brenton(Cancer Research UK), Zoltán Szállási(Harvard University), Julian Downward(Cancer Research UK)
Proceedings of the National Academy of Sciences
May 20, 2009
Cited by 297Open Access
Full Text

Abstract

Microtubule-stabilizing (MTS) agents, such as taxanes, are important chemotherapeutics with a poorly understood mechanism of action. We identified a set of genes repressed in multiple cell lines in response to MTS agents and observed that these genes are overexpressed in tumors exhibiting chromosomal instability (CIN). Silencing 22/50 of these genes, many of which are involved in DNA repair, caused cancer cell death, suggesting that these genes are involved in the survival of aneuploid cells. Overexpression of these "CIN-survival" genes is associated with poor outcome in estrogen receptor-positive breast cancer and occurs frequently in basal-like and Her2-positive cases. In diploid cells, but not in chromosomally unstable cells, paclitaxel causes repression of CIN-survival genes, followed by cell death. In the OV01 ovarian cancer clinical trial, a high level of CIN was associated with taxane resistance but carboplatin sensitivity, indicating that CIN may determine MTS response in vivo. Thus, pretherapeutic assessment of CIN may optimize treatment stratification and clinical trial design using these agents.


Related Papers

No related papers found

Powered by citation graph analysis